Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Live Nation, Ticketmaster Bid to Dismiss FTC Suit Denied

Live Nation, Ticketmaster Bid to Dismiss FTC Suit Denied

MT newswireMT newswire2026/09/29 17:07
01:07 PM EDT, 09/29/2026 (MT Newswires) -- The motion filed by Live Nation Entertainment (LYV) and its unit, Ticketmaster, to dismiss a lawsuit brought by the Federal Trade Commission and several states was denied Monday by a federal judge in California. In the suit, the plaintiffs accuse Live Nation and Ticketmaster of colluding with ticket brokers to drive up prices, according to court documents. Judge Maame Ewusi-Mensah Frimpong wrote in her ruling that this is not the stage of the lawsuit at which Live Nation and Ticketmaster can explain why the FTC's and the states' accusations are false. "At this stage, Live Nation and Ticketmaster are only arguing that even if everything the FTC and the states say in their lawsuit is true, none of that violates the laws referenced," the ruling said. Price: 170.81, Change: -1.08, Percent Change: -0.63
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56